Medical Condition News

RSS

Scientists identify how dihydromyricetin counteracts acute alcohol intoxication

UCLA researchers have identified how a component of an ancient Chinese herbal anti-hangover medicine called dihydromyricetin, isolated from the plant Hovenia, counteracts acute alcohol intoxication and withdrawal symptoms.

6 Jan 2012

Fibroblasts play an apparent role in melanoma tumor growth

Fibroblasts, cells that play a role in the structural framework of tissues, play an apparent role in melanoma tumor growth. Fibroblasts also contribute to melanoma drug resistance and may also facilitate the "flare" response when a tumor's metabolism is enhanced following a patient being removed from a targeted therapy, said researchers at Moffitt Cancer Center in Tampa, Fla.

6 Jan 2012

AACR, IASLC sponsor conference on molecular origins of lung cancer

Lung cancer is the most commonly diagnosed cancer in the United States and often the most fatal unless caught early, but scientists are working on ways to improve their understanding of the disease. Several hundred of scientists will gather in San Diego at the San Diego Marriott Marquis & Marina during Jan. 8-11, 2012, for the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine.

6 Jan 2012

Isis announces results from ISIS-TTRRx Phase 1 study on TTR amyloidosis

Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.

6 Jan 2012

LCA calls for more aggressive integration of imaging advances and biomedical research

As the War on Cancer enters its fifth decade and the number of people being diagnosed with cancer continues to rise, Lung Cancer Alliance (LCA) called for more aggressive integration of advanced imaging technology and biomedical research to improve prevention, earlier detection and treatment of cancer.

6 Jan 2012

Royals designated hitter to receive 47th annual Hutch Award

Billy Butler, designated hitter for the Kansas City Royals, will receive the 47th annual Hutch Award. The award is given each year to a Major League Baseball player who best exemplifies the honor, courage and dedication of baseball great Fred Hutchinson, both on and off the field.

6 Jan 2012

Wake Forest Baptist participates in novel brain tumor vaccine clinical trial

A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate.

6 Jan 2012

Pfizer commences PF-05280602 Phase 1 trial in hemophilia A & B

Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences.

6 Jan 2012

Solar power can make hemodialysis treatments more environmentally friendly

Solar power can help offset high utility costs and make hemodialysis treatments more environmentally friendly, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

6 Jan 2012

New guideline on management of hyperglycemia in non-critically ill hospitalized patients

Hyperglycemia, or having high glucose levels in the blood, is a common, serious and costly health care problem in hospitalized patients. Today, The Endocrine Society released a clinical practice guideline (CPG) providing recommendations for practical and safe glycemic targets and describing protocols and system improvements required to achieve glycemic goals for hospitalized patients in a non-critical care setting.

6 Jan 2012

New anti-tumor compounds show promise for hard-to-treat cancers

New anti-tumor compounds produced by Dr. Aleem Gangjee, Distinguished Professor of Medicinal Pharmacy at Duquesne University's Mylan School of Pharmacy, show such promise for fighting hard-to-treat tumors that the National Institutes of Health (NIH) has placed them on its fast track for development.

6 Jan 2012

Two non-profit organizations to address critical shortage of funding for pediatric cancer research

Two non-profit organizations committed to eliminating cancer in children and young adults have joined together to address the critical shortage of funding for pediatric cancer research.

6 Jan 2012

New laboratory approach could aid brain recovery

In humans, active periods of the debilitating disease Multiple Sclerosis (MS) can last for mere minutes or extend to weeks at a time. They're caused by lesions in the brain that develop, partly heal, and then recur. Research into a cure has been difficult, because to date scientists have not been able to replicate these brain recurring symptoms in laboratory mice. That's frustrating because these lab animals, known as animal "models," are the primary tool for research into the mechanisms and potential treatments for MS.

6 Jan 2012

AstraZeneca plans to progress Targacept's AZD1446 as treatment for AD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that AstraZeneca has informed the company that it plans to progress the development of Targacept's product candidate AZD1446 as a treatment for Alzheimer's disease.

5 Jan 2012

CRF sponsors Seventh International Conference on Cell Therapy for Cardiovascular Disease

The Seventh International Conference on Cell Therapy for Cardiovascular Disease sponsored by the Cardiovascular Research Foundation (CRF) is a comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke.

5 Jan 2012